The product is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses
Lupin has received final approval from the US health regulator to market Clobetasol Propionate ointment, used to treat inflammation and itching caused by a number of skin conditions, in the American market. The company has received final approval from the US Food and Drug Administration (US FDA) for its product which is a generic version of Fougera Pharmaceuticals’ Temovate ointment, Lupin Ltd said in a statement.
The product is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. According to MAT sales data, Clobetasol Propionate ointment had annual sales of around $120 million in the US.
Comments are closed.